Drugmakers are often great dividend payers, and AbbVie and Gilead are among the best. AbbVie sales are currently dropping, but that shouldn't last for too long.

Medicare on Tuesday announced the first 10 drugs selected for price negotiations, launching a historic and highly contentious process with big implications for pharmaceutical companies, taxpayers a...

With summer coming to an end, investors may want to target certain compelling stocks to buy now. Basically, the theory is the reverse of the adage, sell in May and go away.

Investors aren't giving AbbVie nearly enough credit for its post-Humira strategy. CRISPR Therapeutics' pipeline offers stronger prospects than its stock performance indicates.

In the fast-paced arena of stock trading, a glittering prize awaits those with the acumen to spot it: affordable growth stocks.

AbbVie's (ABBV) newer products, Skyrizi and Rinvoq, are performing extremely well and have the potential to make up for lost Humira revenues.

AbbVie investors have good reason to be concerned about the company's future return potential. Sales are expected to fall markedly this year due to the patent expiration of Humira in domestic marke...

If you have the temptation to speculate, but are hesitant to go full bore into the madness of memes, oversold high-yield stocks to buy offer plenty of punch. Specifically, I'm focusing on well-esta...

When it comes to investing in dividend stocks, some investors focus mainly on yield. This can sometimes lead to investing too heavily in stocks that, while offering a high yield, could end up becom...

Large-cap pharmaceuticals have enjoyed buying pressure over the last month, delivering outsized gains to investors. And these three stocks have helped lead the charge.

A trillion-dollar valuation by a single company was once unthinkable even just a few years ago. After all, the S&P 500 was created in 1957 when the total market capitalization of the index was $172...

Following the approval, AbbVie's (ABBV) Aquipta is the first and the only oral CGRP receptor antagonist approved in the EU to prevent episodic and chronic migraines.

The bulk of the Q2 season is in the rearview mirror, but the quarterly results from these 3 Dividend Aristocrats shouldn't be ignored.

There's a reasonable argument to be made that investors should load up on blue-chip stocks regularly. After all, large and well-established firms with long track records of success are likely to co...

While optimism in the broader market remains robust – particularly for hyped-up sectors like technology – investors may still want to consider the relative safety of dividend stocks to buy. Notably...